Literature DB >> 20616219

Severe congenital neutropenia resulting from G6PC3 deficiency with increased neutrophil CXCR4 expression and myelokathexis.

David H McDermott1, Suk See De Ravin, Hyun Sik Jun, Qian Liu, Debra A Long Priel, Pierre Noel, Clifford M Takemoto, Teresa Ojode, Scott M Paul, Kimberly P Dunsmore, Dianne Hilligoss, Martha Marquesen, Jean Ulrick, Douglas B Kuhns, Janice Y Chou, Harry L Malech, Philip M Murphy.   

Abstract

Mutations in more than 15 genes are now known to cause severe congenital neutropenia (SCN); however, the pathologic mechanisms of most genetic defects are not fully defined. Deficiency of G6PC3, a glucose-6-phosphatase, causes a rare multisystem syndrome with SCN first described in 2009. We identified a family with 2 children with homozygous G6PC3 G260R mutations, a loss of enzymatic function, and typical syndrome features with the exception that their bone marrow biopsy pathology revealed abundant neutrophils consistent with myelokathexis. This pathologic finding is a hallmark of another type of SCN, WHIM syndrome, which is caused by gain-of-function mutations in CXCR4, a chemokine receptor and known neutrophil bone marrow retention factor. We found markedly increased CXCR4 expression on neutrophils from both our G6PC3-deficient patients and G6pc3(-/-) mice. In both patients, granulocyte colony-stimulating factor treatment normalized CXCR4 expression and neutrophil counts. In G6pc3(-/-) mice, the specific CXCR4 antagonist AMD3100 rapidly reversed neutropenia. Thus, myelokathexis associated with abnormally high neutrophil CXCR4 expression may contribute to neutropenia in G6PC3 deficiency and responds well to granulocyte colony-stimulating factor.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20616219      PMCID: PMC2974587          DOI: 10.1182/blood-2010-01-265942

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  36 in total

Review 1.  5. Mechanisms of disordered granulopoiesis in congenital neutropenia.

Authors:  David S Grenda; Daniel C Link
Journal:  Curr Top Dev Biol       Date:  2006       Impact factor: 4.897

2.  Trimethoprim-sulfamethoxazole prophylaxis in the management of chronic granulomatous disease.

Authors:  D M Margolis; D A Melnick; D W Alling; J I Gallin
Journal:  J Infect Dis       Date:  1990-09       Impact factor: 5.226

3.  Cellular composition of the bone marrow in normal infants and children.

Authors:  K GLASER; L R LIMARZI; H G PONCHER
Journal:  Pediatrics       Date:  1950-11       Impact factor: 7.124

Review 4.  Genotype/phenotype correlation in glycogen storage disease type 1b: a multicentre study and review of the literature.

Authors:  Daniela Melis; Rossella Fulceri; Giancarlo Parenti; Paola Marcolongo; Rosanna Gatti; Rossella Parini; Enrica Riva; Roberto Della Casa; Enrico Zammarchi; Generoso Andria; Angelo Benedetti
Journal:  Eur J Pediatr       Date:  2005-05-19       Impact factor: 3.183

5.  A pharmacokinetic-pharmacodynamic model for the mobilization of CD34+ hematopoietic progenitor cells by AMD3100.

Authors:  N A Lack; B Green; D C Dale; G B Calandra; H Lee; R T MacFarland; K Badel; W C Liles; G Bridger
Journal:  Clin Pharmacol Ther       Date:  2005-05       Impact factor: 6.875

6.  G-CSF potently inhibits osteoblast activity and CXCL12 mRNA expression in the bone marrow.

Authors:  Craig L Semerad; Matthew J Christopher; Fulu Liu; Brenton Short; Paul J Simmons; Ingrid Winkler; Jean-Pierre Levesque; Jean Chappel; F Patrick Ross; Daniel C Link
Journal:  Blood       Date:  2005-07-21       Impact factor: 22.113

7.  G-CSF down-regulation of CXCR4 expression identified as a mechanism for mobilization of myeloid cells.

Authors:  Hyun Kyung Kim; Maria De La Luz Sierra; Cassin Kimmel Williams; A Virginia Gulino; Giovanna Tosato
Journal:  Blood       Date:  2006-03-14       Impact factor: 22.113

8.  Mutations in the glucose-6-phosphatase gene that cause glycogen storage disease type 1a.

Authors:  K J Lei; L L Shelly; C J Pan; J B Sidbury; J Y Chou
Journal:  Science       Date:  1993-10-22       Impact factor: 47.728

9.  The incidence of leukemia and mortality from sepsis in patients with severe congenital neutropenia receiving long-term G-CSF therapy.

Authors:  Philip S Rosenberg; Blanche P Alter; Audrey A Bolyard; Mary Ann Bonilla; Laurence A Boxer; Bonnie Cham; Carol Fier; Melvin Freedman; George Kannourakis; Sally Kinsey; Beate Schwinzer; Connie Zeidler; Karl Welte; David C Dale
Journal:  Blood       Date:  2006-02-23       Impact factor: 22.113

10.  Infantile genetic agranulocytosis; agranulocytosis infantilis hereditaria.

Authors:  R KOSTMANN
Journal:  Acta Paediatr Suppl       Date:  1956-02
View more
  38 in total

1.  WHIM syndrome caused by a single amino acid substitution in the carboxy-tail of chemokine receptor CXCR4.

Authors:  Qian Liu; Haoqian Chen; Teresa Ojode; Xiangxi Gao; Sandra Anaya-O'Brien; Nicholas A Turner; Jean Ulrick; Rosamma DeCastro; Corin Kelly; Adela R Cardones; Stuart H Gold; Eugene I Hwang; Daniel S Wechsler; Harry L Malech; Philip M Murphy; David H McDermott
Journal:  Blood       Date:  2012-05-17       Impact factor: 22.113

Review 2.  Genetics on a WHIM.

Authors:  Omar Al Ustwani; Razelle Kurzrock; Meir Wetzler
Journal:  Br J Haematol       Date:  2013-09-20       Impact factor: 6.998

3.  Glucose-6-phosphatase-β, implicated in a congenital neutropenia syndrome, is essential for macrophage energy homeostasis and functionality.

Authors:  Hyun Sik Jun; Yuk Yin Cheung; Young Mok Lee; Brian C Mansfield; Janice Y Chou
Journal:  Blood       Date:  2012-01-12       Impact factor: 22.113

4.  SRP54 mutations induce congenital neutropenia via dominant-negative effects on XBP1 splicing.

Authors:  Christoph Schürch; Thorsten Schaefer; Joëlle S Müller; Pauline Hanns; Marlon Arnone; Alain Dumlin; Jonas Schärer; Irmgard Sinning; Klemens Wild; Julia Skokowa; Karl Welte; Raphael Carapito; Seiamak Bahram; Martina Konantz; Claudia Lengerke
Journal:  Blood       Date:  2021-03-11       Impact factor: 22.113

Review 5.  New monogenic disorders identify more pathways to neutropenia: from the clinic to next-generation sequencing.

Authors:  Seth J Corey; Usua Oyarbide
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2017-12-08

6.  The leukocyte chemotactic receptor FPR1 is functionally expressed on human lens epithelial cells.

Authors:  Erich H Schneider; Joseph D Weaver; Sonia S Gaur; Brajendra K Tripathi; Algirdas J Jesaitis; Peggy S Zelenka; Ji-Liang Gao; Philip M Murphy
Journal:  J Biol Chem       Date:  2012-09-25       Impact factor: 5.157

7.  Phenotypic heterogeneity and evidence of a founder effect associated with G6PC3 mutations in patients with severe congenital neutropenia.

Authors:  Bradley N Smith; Catherine Evans; Akbar Ali; Phil J Ancliff; Bu'hussain Hayee; Anthony W Segal; Georgina Hall; Zuhre Kaya; Abdul Rauf Shakoori; David C Linch; Rosemary E Gale
Journal:  Br J Haematol       Date:  2012-04-02       Impact factor: 6.998

8.  Functional analysis of mutations in a severe congenital neutropenia syndrome caused by glucose-6-phosphatase-β deficiency.

Authors:  Su Ru Lin; Chi-Jiunn Pan; Brian C Mansfield; Janice Yang Chou
Journal:  Mol Genet Metab       Date:  2014-11-26       Impact factor: 4.797

9.  Survival and differentiation defects contribute to neutropenia in glucose-6-phosphatase-β (G6PC3) deficiency in a model of mouse neutrophil granulocyte differentiation.

Authors:  S Gautam; S Kirschnek; I E Gentle; C Kopiniok; P Henneke; H Häcker; L Malleret; A Belaaouaj; G Häcker
Journal:  Cell Death Differ       Date:  2013-05-17       Impact factor: 15.828

10.  A novel homozygous mutation in G6PC3 presenting as cyclic neutropenia and severe congenital neutropenia in the same family.

Authors:  Abdullah A Alangari; Abdulrahman Alsultan; Mohamed Elfaki Osman; Shamsa Anazi; Fowzan S Alkuraya
Journal:  J Clin Immunol       Date:  2013-10-09       Impact factor: 8.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.